Obestatin does not modify weight and nutritional behaviour but is associated with metabolic syndrome in old women. (25th March 2013)

• Record Type: Journal Article
• Authors: Mora, Mireia; Granada, Maria L.; Roca, Maria; Palomera, Elisabet; Puig, Rocio; Serra‐Prat, Mateu; Puig‐Domingo, Manel
• Is Part Of: Clinical endocrinology. Volume 78:Number 6(2013:Jun.)
• Page Start: 882
• Page End: 890
• Publication Date: 2013-03-25
• Subjects: Endocrinology -- Periodicals; 616.4005
• DOI: 10.1111/j.1365-2265.2012.04489.x
• Languages: English
• ISSNs: 0300-0664

Abstract

<abstract abstract-type="main" id="cen4489-abs-0001"> <title>Summary</title> <sec id="cen4489-sec-0001" sec-type="section"> <title>Objective</title> <p>Ghrelin and obestatin have apparent opposite orexigenic and anorexigenic effects, although the latter has not been firmly demonstrated in humans. So far, little data have been reported in relation to its potential association with metabolic syndrome (MS). The objective was to study obestatin concentrations in relation to nutritional parameters and eating behaviours in old women.</p> </sec> <sec id="cen4489-sec-0002" sec-type="section"> <title>Design, Patients and Measurements</title> <p>Prospective study; a total of 110 women (age: 76·93 ± 6·32) from the Mataró Ageing Study were included. Individuals were characterized by anthropometric variables, lipids, glucose, blood pressure, MS components (Adult Treatment Panel III criteria), anorexia and nutritional status by Mini Nutritional Assessment Short Form (MNA‐SF) and re‐evaluated at 2‐year follow‐up. Obestatin was measured by IRMA.</p> </sec> <sec id="cen4489-sec-0003" sec-type="section"> <title>Results</title> <p>58·2% of the subjects had MS; at 2‐year follow‐up 24·1% had a weight loss >5%, 7·2% >10%, and 26·4% changed their MNA‐SF score to risk of malnutrition category. Anorexia was present in 38·4%. Obestatin levels were not related to either change of weight, MNA‐SF or anorexia, but a positive correlation was found with the absolute difference between basal and 2‐year waist circumference (WC) (<italic>r</italic> = 0·429; <italic>P</italic> < 0·001) and relative difference between basal and 2‐year WC (<italic>r</italic> = 0·420; <italic>P</italic> < 0·001); both remained significant after adjusting for age and body mass index. When obestatin was divided into quartiles, a significant lineal trend was observed in relation to WC (<italic>P</italic> = 0·049), absolute and relative difference between basal and 2‐year WC (both <italic>P</italic> < 0·001). Obestatin was associated with glucose impairment (69·0% in 4th quartile <italic>vs</italic> 47·5% in 1st to 3rd, <italic>P</italic> = 0·047; after adjustment, <italic>P</italic> = 0·098) and MS (77·8% in 4th <italic>vs</italic> 51·3% in 1st to 3rd, <italic>P</italic> = 0·017; after adjustment, <italic>P</italic> = 0·046, OR 2·90 (1·02–8·25) 4th <italic>vs</italic> 1st to 3rd).</p> </sec> <sec id="cen4489-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Obestatin is elevated in aged women bearing MS but is otherwise not associated with other nutritional parameters, weight loss or anorexia.</p> </sec> </abstract>